MHRA’s guidance on EU paediatric compliance
This article was originally published in Scrip
Executive Summary
Before submitting a marketing authorisation to the UKMHRA, the agency strongly advises pharmaceutical companies to seek an opinion from theEMEA's paediatric committee on whether the application complies with the paediatric investigation plan (PIP), otherwise the MHRA itself will submit it to the committee.